- Home
- DRMA vs IVP Comparison
DRMA vs IVP Comparison
Compare DRMA & IVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- IVP
- Stock Information
- Founded
- DRMA 2014
- IVP 2020
- Country
- DRMA United States
- IVP United States
- Employees
- DRMA N/A
- IVP N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- IVP Diversified Commercial Services
- Sector
- DRMA Health Care
- IVP Miscellaneous
- Exchange
- DRMA Nasdaq
- IVP Nasdaq
- Market Cap
- DRMA 3.3M
- IVP 3.6M
- IPO Year
- DRMA 2021
- IVP 2023
- Fundamental
- Price
- DRMA $5.38
- IVP N/A
- Analyst Decision
- DRMA Strong Buy
- IVP
- Analyst Count
- DRMA 1
- IVP 0
- Target Price
- DRMA $10.00
- IVP N/A
- AVG Volume (30 Days)
- DRMA 79.8K
- IVP 171.2K
- Earning Date
- DRMA 11-12-2025
- IVP 11-12-2025
- Dividend Yield
- DRMA N/A
- IVP N/A
- EPS Growth
- DRMA N/A
- IVP N/A
- EPS
- DRMA N/A
- IVP N/A
- Revenue
- DRMA N/A
- IVP $15,292,904.00
- Revenue This Year
- DRMA N/A
- IVP N/A
- Revenue Next Year
- DRMA N/A
- IVP N/A
- P/E Ratio
- DRMA N/A
- IVP N/A
- Revenue Growth
- DRMA N/A
- IVP N/A
- 52 Week Low
- DRMA $4.55
- IVP $0.63
- 52 Week High
- DRMA $23.70
- IVP $24.61
- Technical
- Relative Strength Index (RSI)
- DRMA 50.49
- IVP 55.92
- Support Level
- DRMA $4.55
- IVP $0.88
- Resistance Level
- DRMA $5.22
- IVP $1.06
- Average True Range (ATR)
- DRMA 0.44
- IVP 0.09
- MACD
- DRMA 0.02
- IVP 0.00
- Stochastic Oscillator
- DRMA 58.04
- IVP 42.11
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.